Q4FY19 results: Kilitch Drugs India registers 42.68 pct growth in operational income

The Board of Directors of Kilitch Drugs India Limited announced its standalone along with consolidated results for the fourth quarter and year ended March 31, 2019 following its approval by the Board of Directors in a meeting held in Mumbai today. For the fourth quarter ended March 31, 2019, standalone revenue from operations was at Rs 22.33 crore as against Rs 15.70 crore, recording an increase of 42.68 per cent. Standalone Net Profit after tax was at Rs 2.65 crore for the quarter ended March 31, 2019 as compared to Rs 2.28 crore in the previous corresponding quarter. EBITDA stood at Rs 3.53 crore in the quarter ended March 31, 2019 as against Rs 3.05 crore in the previous corresponding quarter.

Source: Kilitch Drugs

Speaking on the development Mukund Mehta, Managing Director at Kilitch Drugs (India) Ltd said, “Our growth momentum continued during the financial year despite the challenging business environment across different markets. During the year, we took a strategic step of building our new facility in Ethiopia. We believe this will help accelerate the growth of the overall organization.” 

For the year ended March 31, 2019, Kilitch Drugs (India) Ltd published its consolidated revenue of Rs 86.49 crore as against Rs 53.88 crore, recording an increase of 60.52% over the previous corresponding period. Consolidated Net Profit was at Rs 3.82 crore for the year ended March 31, 2019, as against Rs 5.15 crore in the previous year. Consolidated EBITDA for the fiscal year ended March 31, 2019 stood at Rs 8.58 crore as against Rs 6.11 crore in the previous corresponding period. 

The Board of Directors have recommended a dividend of Rs 0.50 per share of face value Rs 10, subject to shareholders approval.